Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
13400 participants
OBSERVATIONAL
2020-09-27
2024-11-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The data collected from all the studies will then be analysed to see if patient groups can be identified who are at risk of poorer quality of life and worse health outcomes. These groups can then be targeted with the aim of improving their health outcomes.
The study will use statistical methods to look at the relationship of factors such asÍž medication adherence, comorbidities and patient demographics on health-related quality of life and health outcomes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-term Follow-up of Health Related Quality of Life in Patients With Acute Coronary Syndrome
NCT01955525
Measurement of Matrix Metalloproteinase Activation Post Myocardial Infarction
NCT00576121
Investigating Variation in Hospital Acute Coronary Syndrome Outcomes
NCT01808027
Quality of Life in Patients With Chronic Ischemic Heart Disease
NCT00005671
Survival and cArdiovascular eVents in Patients With Acute Myocardial Infarction
NCT06489080
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Research has shown that changes in HRQoL are associated with a range of clinical outcomes, including death, anxiety and depression, and medications compliance. Changes in HRQoL have been reported to negatively impact healthcare costs, and employment. However, there is a paucity of information about the relationship between HRQoL and clinical outcomes inherent following MI. Moreover, previous research is limited by small sample sizes, poor generalisability,selection bias, the use of retrospective cross-sectional designs,and short follow-up durations of 6 months - 2 years. For example in our previous studies (EMMACE 3 and 4 ), we followed up patients for up to 2 years. The EMMACE data analysis showed that over two years HRQoL improved for the majority (two thirds) but was significantly worse and more likely to decline for women, NSTEMI, and people with long-term health conditions .
Whilst the analysis of EMMACE demonstrates promising results, the EMMACE data are limited by the short follow up period of up to 2 years. We have been funded by the British Heart Foundation (Program grant number PG/19/54/34511) to link the EMMACE 3 and 4 data to ONS (mortality) and Hospital Episode Statistics (HES) data such that longer-term non-fatal and fatal outcomes and healthcare utilisation may be studied. All patients were consented to enter the EMMACE 3 and 4 studies and for their self-reported data to be linked to future electronic health record data. EMMACE data has already been successfully linked to data from the national heart attack registry (Myocardial Ischemia National Audit project, MINAP) thus providing information about hospital treatment for MI and comorbidities. This study will provide a further follow up of this data so that longer term follow up can be studied.
To complement our work, and given the paucity on longer term HRQoL data, in this proposal we aim to collect \> 5 years HRQoL measures data from the participants of EMMACE 3 \& 4 studies. The longer follow up of HRQoL data (\> 5 years) may provide insights into understanding the association between long term changes in HRQoL and subsequent clinical outcomes and precisely in whom worse (or better) outcomes may occur will permit the design and testing of novel intervention to reduce premature death from MI.
The planned research will provide unique and comprehensive insight into the relationship between changes in HRQoL and survival following MI. Health-related quality of life is a patient reported outcome measure (PROM) which can detect change in risk of events for patients, and potentially serve as a predictor of future risk (using patient-facing data capture tools). Understanding the association between changes in HRQoL and health outcomes and precisely in whom worse (or better) outcomes may occur will permit the design and testing of novel interventions to reduce premature death from MI.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EMMACE 3
Participants who were recruited to the EMMACE 3 study and have agreed to contact for further research.
Questionnaire
Patients will complete an EQ-5D questionnaire, medication and lifestyle questions
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Questionnaire
Patients will complete an EQ-5D questionnaire, medication and lifestyle questions
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
\-
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Leeds
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Christopher Gale
Professor of Cardiovascular Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chris P Gale, Prof
Role: PRINCIPAL_INVESTIGATOR
University of Leeds
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Leeds
Leeds, West Yorkshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Alabas OA, West RM, Gillott RG, Khatib R, Hall AS, Gale CP; EMMACE-3 Investigators. Evaluation of the Methods and Management of Acute Coronary Events (EMMACE)-3: protocol for a longitudinal study. BMJ Open. 2015 Jun 23;5(6):e006256. doi: 10.1136/bmjopen-2014-006256.
Munyombwe T, Hall M, Dondo TB, Alabas OA, Gerard O, West RM, Pujades-Rodriguez M, Hall A, Gale CP. Quality of life trajectories in survivors of acute myocardial infarction: a national longitudinal study. Heart. 2020 Jan;106(1):33-39. doi: 10.1136/heartjnl-2019-315510. Epub 2019 Nov 7.
Dondo TB, Munyombwe T, Hall M, Hurdus B, Soloveva A, Oliver G, Aktaa S, West RM, Hall AS, Gale CP. Sex differences in health-related quality of life trajectories following myocardial infarction: national longitudinal cohort study. BMJ Open. 2022 Nov 8;12(11):e062508. doi: 10.1136/bmjopen-2022-062508.
Related Links
Access external resources that provide additional context or updates about the study.
Activities of the team and link to study information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
276202
Identifier Type: OTHER
Identifier Source: secondary_id
PG/19/54/34511
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
20/PR/0104
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.